Xeris Biopharma Holdings (XERS) EBIT Margin (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted EBIT Margin of 9.52% for Q1 2026, down 51.28% on a QoQ basis from 19.55% in Q4 2025, and up 1466.0% year-over-year from 0.61% in Q1 2025.
Xeris Biopharma Holdings (XERS) EBIT Margin (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' EBIT Margin history runs 7 years deep, the most recent figure standing at 9.52% for Q1 2026.
- Quarterly EBIT Margin rose 1466.0% year-over-year to 9.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.4% (up 2151.0% YoY) and the FY2025 annual result came in at 8.53%, up 2510.0% from the prior year.
- EBIT Margin was 9.52% for Q1 2026 at Xeris Biopharma Holdings, down from 19.55% in the prior quarter.
- Across five years, EBIT Margin topped out at 19.55% in Q4 2025 and bottomed at 131.72% in Q1 2022.
- A 5-year average of 27.27% and a median of 22.17% in 2023 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2022 — EBIT Margin surged 21480 bps — and 2024, when it slumped 1359 bps.
- Xeris Biopharma Holdings' EBIT Margin stood at 45.77% in 2022, then surged by 52 bps to 22.17% in 2023, then soared by 113 bps to 2.79% in 2024, then soared by 600 bps to 19.55% in 2025, then slumped by 51 bps to 9.52% in 2026.
- Business Quant data shows XERS's EBIT Margin at 9.52% in Q1 2026, 19.55% in Q4 2025, and 9.05% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | 9.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.52% |
| Dec 31, 2025 | 19.55% |
| Sep 30, 2025 | 9.05% |
| Jun 30, 2025 | 6.27% |
| Mar 31, 2025 | -5.14% |
| Dec 31, 2024 | 2.79% |
| Sep 30, 2024 | -23.76% |
| Jun 30, 2024 | -17.03% |
| Mar 31, 2024 | -35.05% |
| Dec 31, 2023 | -22.17% |
| Sep 30, 2023 | -10.17% |
| Jun 30, 2023 | -42.04% |
| Mar 31, 2023 | -40.00% |
| Dec 31, 2022 | -45.77% |
| Sep 30, 2022 | -63.18% |
| Jun 30, 2022 | -74.75% |
| Mar 31, 2022 | -131.72% |
| Dec 31, 2021 | -225.26% |
| Sep 30, 2021 | -220.24% |
| Jun 30, 2021 | -289.55% |